Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis

Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone o...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2020-08, Vol.34 (S6), p.10-16
Main Authors: Thouvenin, M.D., Dalmon, S., Theunis, J., Lauze, C., Coubetergues, H., Mengeaud, V., Calvet, B.
Format: Article
Language:English
Subjects:
Adult
Humans
Pentacyclic Triterpenes - therapeutic use
Psoriasis - drug therapy
Quality of Life
Treatment Outcome
Triterpenes - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3
cites cdi_FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3
container_end_page 16
container_issue S6
container_start_page 10
container_title Journal of the European Academy of Dermatology and Venereology
container_volume 34
creator Thouvenin, M.D.
Dalmon, S.
Theunis, J.
Lauze, C.
Coubetergues, H.
Mengeaud, V.
Calvet, B.
description Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone or in association with topical or systemic drug treatments or phototherapy, and its efficacy when used alone. Methods Adults with body plaque psoriasis applied the product over the whole body once a day for 4 weeks (balm used alone in 41 patients and with ongoing treatment in 50 patients). At D1, D8 (‘balm alone’ study) or D15 (‘balm in association’ study) and D29, the dermatologist rated physical and functional signs and assessed pruritus and body global lesion score (evaluating erythema, induration/thickness, scaling and dryness) in the ‘balm alone’ study. Results No reaction related to the product was reported, and the tolerance was deemed excellent. In the ‘balm alone’ study, mean pruritus intensity score significantly decreased at D8 (−39%, P 
doi_str_mv 10.1111/jdv.16691
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2433240340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2433240340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3</originalsourceid><addsrcrecordid>eNp1kMtKAzEUQIMotlYX_oBkqYtp85rXUuqbgpsi7oY7yR1JmcnUpGPpzk_wG_0SR1vdGS4ELofD5RByytmY92-yMG9jniQ53yNDrpIskiyT-2TIcpFEeR7nA3IUwoIxxnmcHZKBFGkmRaKG5Hne1ujBaaTgDMWqshr0hrYVBepwTTXWEFa-rT_fP3TrVmCddS-0hLqhECiYRef0imrwSK2jy9B6C8GGY3JQQR3wZPePyPzmej69i2aPt_fTy1mkZcJ4pHiaJhU3Ko5Trg2kRqFBhaIScSlYUrK85P2KZQqUSHOuUmk4KJQMU2HkiJxvtUvfvnYYVkVjQ39zDQ7bLhRCSSkUk_2MyMUW1b4NwWNVLL1twG8KzorvjkXfsfjp2LNnO21XNmj-yN9wPTDZAmtb4-Z_U_Fw9bRVfgEWonz9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2433240340</pqid></control><display><type>article</type><title>Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis</title><source>Wiley</source><creator>Thouvenin, M.D. ; Dalmon, S. ; Theunis, J. ; Lauze, C. ; Coubetergues, H. ; Mengeaud, V. ; Calvet, B.</creator><creatorcontrib>Thouvenin, M.D. ; Dalmon, S. ; Theunis, J. ; Lauze, C. ; Coubetergues, H. ; Mengeaud, V. ; Calvet, B.</creatorcontrib><description>Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone or in association with topical or systemic drug treatments or phototherapy, and its efficacy when used alone. Methods Adults with body plaque psoriasis applied the product over the whole body once a day for 4 weeks (balm used alone in 41 patients and with ongoing treatment in 50 patients). At D1, D8 (‘balm alone’ study) or D15 (‘balm in association’ study) and D29, the dermatologist rated physical and functional signs and assessed pruritus and body global lesion score (evaluating erythema, induration/thickness, scaling and dryness) in the ‘balm alone’ study. Results No reaction related to the product was reported, and the tolerance was deemed excellent. In the ‘balm alone’ study, mean pruritus intensity score significantly decreased at D8 (−39%, P &lt; 0.001) and D29 (−60%, P &lt; 0.001) compared with D1, together with the body global lesion score (−24% at D8 and −26% at D29, P &lt; 0.001). In parallel, quality of life improved, as evidenced by a patient‐reported outcome questionnaire. Cosmetic acceptability was good. Conclusion This new emollient balm was very well tolerated by patients with body plaque psoriasis either alone or in association with drug treatment or phototherapy, which is important to ensure long‐term compliance. Daily application during one month improved pruritus, physical signs and quality of life.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16691</identifier><identifier>PMID: 32783264</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Humans ; Pentacyclic Triterpenes - therapeutic use ; Psoriasis - drug therapy ; Quality of Life ; Treatment Outcome ; Triterpenes - therapeutic use</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-08, Vol.34 (S6), p.10-16</ispartof><rights>2020 European Academy of Dermatology and Venereology</rights><rights>2020 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3</citedby><cites>FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32783264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thouvenin, M.D.</creatorcontrib><creatorcontrib>Dalmon, S.</creatorcontrib><creatorcontrib>Theunis, J.</creatorcontrib><creatorcontrib>Lauze, C.</creatorcontrib><creatorcontrib>Coubetergues, H.</creatorcontrib><creatorcontrib>Mengeaud, V.</creatorcontrib><creatorcontrib>Calvet, B.</creatorcontrib><title>Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone or in association with topical or systemic drug treatments or phototherapy, and its efficacy when used alone. Methods Adults with body plaque psoriasis applied the product over the whole body once a day for 4 weeks (balm used alone in 41 patients and with ongoing treatment in 50 patients). At D1, D8 (‘balm alone’ study) or D15 (‘balm in association’ study) and D29, the dermatologist rated physical and functional signs and assessed pruritus and body global lesion score (evaluating erythema, induration/thickness, scaling and dryness) in the ‘balm alone’ study. Results No reaction related to the product was reported, and the tolerance was deemed excellent. In the ‘balm alone’ study, mean pruritus intensity score significantly decreased at D8 (−39%, P &lt; 0.001) and D29 (−60%, P &lt; 0.001) compared with D1, together with the body global lesion score (−24% at D8 and −26% at D29, P &lt; 0.001). In parallel, quality of life improved, as evidenced by a patient‐reported outcome questionnaire. Cosmetic acceptability was good. Conclusion This new emollient balm was very well tolerated by patients with body plaque psoriasis either alone or in association with drug treatment or phototherapy, which is important to ensure long‐term compliance. Daily application during one month improved pruritus, physical signs and quality of life.</description><subject>Adult</subject><subject>Humans</subject><subject>Pentacyclic Triterpenes - therapeutic use</subject><subject>Psoriasis - drug therapy</subject><subject>Quality of Life</subject><subject>Treatment Outcome</subject><subject>Triterpenes - therapeutic use</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKAzEUQIMotlYX_oBkqYtp85rXUuqbgpsi7oY7yR1JmcnUpGPpzk_wG_0SR1vdGS4ELofD5RByytmY92-yMG9jniQ53yNDrpIskiyT-2TIcpFEeR7nA3IUwoIxxnmcHZKBFGkmRaKG5Hne1ujBaaTgDMWqshr0hrYVBepwTTXWEFa-rT_fP3TrVmCddS-0hLqhECiYRef0imrwSK2jy9B6C8GGY3JQQR3wZPePyPzmej69i2aPt_fTy1mkZcJ4pHiaJhU3Ko5Trg2kRqFBhaIScSlYUrK85P2KZQqUSHOuUmk4KJQMU2HkiJxvtUvfvnYYVkVjQ39zDQ7bLhRCSSkUk_2MyMUW1b4NwWNVLL1twG8KzorvjkXfsfjp2LNnO21XNmj-yN9wPTDZAmtb4-Z_U_Fw9bRVfgEWonz9</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Thouvenin, M.D.</creator><creator>Dalmon, S.</creator><creator>Theunis, J.</creator><creator>Lauze, C.</creator><creator>Coubetergues, H.</creator><creator>Mengeaud, V.</creator><creator>Calvet, B.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202008</creationdate><title>Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis</title><author>Thouvenin, M.D. ; Dalmon, S. ; Theunis, J. ; Lauze, C. ; Coubetergues, H. ; Mengeaud, V. ; Calvet, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Humans</topic><topic>Pentacyclic Triterpenes - therapeutic use</topic><topic>Psoriasis - drug therapy</topic><topic>Quality of Life</topic><topic>Treatment Outcome</topic><topic>Triterpenes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thouvenin, M.D.</creatorcontrib><creatorcontrib>Dalmon, S.</creatorcontrib><creatorcontrib>Theunis, J.</creatorcontrib><creatorcontrib>Lauze, C.</creatorcontrib><creatorcontrib>Coubetergues, H.</creatorcontrib><creatorcontrib>Mengeaud, V.</creatorcontrib><creatorcontrib>Calvet, B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thouvenin, M.D.</au><au>Dalmon, S.</au><au>Theunis, J.</au><au>Lauze, C.</au><au>Coubetergues, H.</au><au>Mengeaud, V.</au><au>Calvet, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-08</date><risdate>2020</risdate><volume>34</volume><issue>S6</issue><spage>10</spage><epage>16</epage><pages>10-16</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background In patients with psoriasis, the non‐lesional skin also presents abnormalities, requiring emollient application on the whole body. Objectives To evaluate the tolerance of a new emollient balm containing celastrol, an active ingredient with anti‐Th17 immunomodulatory properties used alone or in association with topical or systemic drug treatments or phototherapy, and its efficacy when used alone. Methods Adults with body plaque psoriasis applied the product over the whole body once a day for 4 weeks (balm used alone in 41 patients and with ongoing treatment in 50 patients). At D1, D8 (‘balm alone’ study) or D15 (‘balm in association’ study) and D29, the dermatologist rated physical and functional signs and assessed pruritus and body global lesion score (evaluating erythema, induration/thickness, scaling and dryness) in the ‘balm alone’ study. Results No reaction related to the product was reported, and the tolerance was deemed excellent. In the ‘balm alone’ study, mean pruritus intensity score significantly decreased at D8 (−39%, P &lt; 0.001) and D29 (−60%, P &lt; 0.001) compared with D1, together with the body global lesion score (−24% at D8 and −26% at D29, P &lt; 0.001). In parallel, quality of life improved, as evidenced by a patient‐reported outcome questionnaire. Cosmetic acceptability was good. Conclusion This new emollient balm was very well tolerated by patients with body plaque psoriasis either alone or in association with drug treatment or phototherapy, which is important to ensure long‐term compliance. Daily application during one month improved pruritus, physical signs and quality of life.</abstract><cop>England</cop><pmid>32783264</pmid><doi>10.1111/jdv.16691</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2020-08, Vol.34 (S6), p.10-16
issn 0926-9959
1468-3083
language eng
recordid cdi_proquest_miscellaneous_2433240340
source Wiley
subjects Adult
Humans
Pentacyclic Triterpenes - therapeutic use
Psoriasis - drug therapy
Quality of Life
Treatment Outcome
Triterpenes - therapeutic use
title Tolerance and efficacy of a new celastrol‐containing balm as adjunct care in psoriasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A15%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tolerance%20and%20efficacy%20of%20a%20new%20celastrol%E2%80%90containing%20balm%20as%20adjunct%20care%20in%20psoriasis&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Thouvenin,%20M.D.&rft.date=2020-08&rft.volume=34&rft.issue=S6&rft.spage=10&rft.epage=16&rft.pages=10-16&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16691&rft_dat=%3Cproquest_cross%3E2433240340%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3601-41776f1d45571cda7d4ede4e2f25b206b09b14ed084a42791473d1a4e30e72d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2433240340&rft_id=info:pmid/32783264&rfr_iscdi=true